Jaguar secures $16M licensing deal, swings to profit, but faces imminent Nasdaq delisting

Filed May 20, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  Received formal Nasdaq delisting notice in March 2026 for bid price below $1.00; executed three reverse splits (cumulative 52,500:1) within two years, triggering accelerated delisting procedures without standard compliance period.

  Risk Factors: Nasdaq Delisting verify on EDGAR →
• high

  Signed $16M upfront licensing deal with Future Pak in January 2026, transferring exclusive US marketing rights for Mytesi and Canalevia-CA1; company retains manufacturing and can earn up to $20M in milestones.

  MD&A: Future Pak Agreement verify on EDGAR →
• high

  Swung to $8.7M net income in Q1 2026 vs. $10.6M loss prior year, driven by $19M license revenue; however, $15.9M in preferred stock dividends resulted in $7.0M net loss to common shareholders.

  MD&A: Financial Results verify on EDGAR →